Olanzapine

Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.(In Vitro):Olanzapine binds weakly to GABAA, Benzodiazepine (BZD), and β-adrenergic receptors (Ki>10 μM) .Olanzapine induces autophagy in human SH-SY5Y neuronal cell line.Olanzapine (1-100 μM for 144 h under serum starvation) results in a marked anti-proliferative effect in glioblastoma cell lines as well as glioma stem-like cells.Olanzapine also enhances Temozolomide’s anti-tumor activity in glioblastoma cell lines.Olanzapine induces apoptosis and necrosis in glioblastoma cell lines.(In Vivo):Olanzapine (0.75, 1.5 and 3 mg/kg) evaluates body weight and periuterine fat mass, as well as insulin, non-esterified fatty acids, triglycerides, and glucose levels in mice.